SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001640334-23-000757 from Lexaria Bioscience Corp. (LEXX, LEXXW) (CIK 0001348362) (LEXX)

Lexaria Bioscience Corp. (LEXX, LEXXW) (CIK 0001348362)
Date: May 3, 2023 · CIK: 0001348362 · Accession: 0001640334-23-000757

AI Filing Summary & Sentiment

File numbers found in text: 333-271096

Date
May 3, 2023
Author
Title: Co-President
Form
CORRESP
Company
Lexaria Bioscience Corp. (LEXX, LEXXW) (CIK 0001348362)

Letter

Re: Lexaria Bioscience Corp.

lexx_corresp.htm

May 3, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-1004

Registration Statement on Form S-1, as amended

File No. 333-271096

Ladies and Gentlemen:

As the placement agent of the proposed offering of Lexaria Bioscience Corp. (the “Company”), we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 9:00 a.m., Eastern Time, on Friday, May 5, 2023, or as soon thereafter as is practicable.

Pursuant to Rule 460 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, we wish to advise you that, through May 3, 2023, we distributed to each dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies, as well as “E-red” copies of the Preliminary Prospectus dated April 28, 2023, as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

.

Very truly yours,
Maxim Group LLC

Show Raw Text
CORRESP
1
filename1.htm

lexx_corresp.htm

 May 3, 2023

 VIA EDGAR

 U.S. Securities and Exchange Commission

 Division of Corporation Finance

 100 F Street, N.E.

 Washington, D.C.  20549-1004

             Re:      Lexaria Bioscience Corp.

                         Registration Statement on Form S-1, as amended

                         File No. 333-271096

 Ladies and Gentlemen:

 As the placement agent of the proposed offering of Lexaria Bioscience Corp. (the “Company”), we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 9:00 a.m., Eastern Time, on Friday, May 5, 2023, or as soon thereafter as is practicable.

 Pursuant to Rule 460 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, we wish to advise you that, through May 3, 2023, we distributed to each dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies, as well as “E-red” copies of the Preliminary Prospectus dated April 28, 2023, as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

 The undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

 .

 Very truly yours,

 Maxim Group LLC

 By: /s/ Clifford A. Teller

 Name: Clifford A. Teller

 Title: Co-President